Wealth Enhancement Advisory Services LLC Invests $97,000 in Monte Rosa Therapeutics, Inc. $GLUE

Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 20,007 shares of the company’s stock, valued at approximately $97,000.

Several other large investors also recently bought and sold shares of the business. BVF Inc. IL grew its stake in Monte Rosa Therapeutics by 104.7% during the 1st quarter. BVF Inc. IL now owns 5,660,132 shares of the company’s stock valued at $26,263,000 after acquiring an additional 2,895,661 shares in the last quarter. Parkwood LLC grew its stake in Monte Rosa Therapeutics by 119.2% during the 1st quarter. Parkwood LLC now owns 708,000 shares of the company’s stock valued at $3,285,000 after acquiring an additional 385,000 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock valued at $1,652,000 after acquiring an additional 196,238 shares in the last quarter. Readystate Asset Management LP purchased a new stake in Monte Rosa Therapeutics during the 1st quarter valued at about $1,332,000. Finally, AQR Capital Management LLC purchased a new stake in Monte Rosa Therapeutics during the 1st quarter valued at about $1,065,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Up 18.7%

Shares of GLUE stock opened at $10.04 on Monday. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.50 and a 52 week high of $12.40. The stock has a market capitalization of $620.07 million, a PE ratio of 27.89 and a beta of 1.54. The firm has a 50 day moving average of $5.70 and a two-hundred day moving average of $5.04.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.16. Monte Rosa Therapeutics had a net margin of 13.58% and a return on equity of 9.95%. The business had revenue of $23.19 million for the quarter, compared to analyst estimates of $7.23 million. Analysts expect that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $15.33.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.